The decision means many Americans without underlying conditions may not have access to updated shots this fall."I think we have to admit to ourselves that America is deeply divided on the policy issue of repeat COVID-19 vaccine doses or boosters,

In an editorial article published in the New England Journal of Medicine, Dr. Vinay Prasad, the newly appointed head of the Center for Biologics Evaluation and research at the FDA, and Dr. Martin Makary, FDA commissioner, explained their plan for how the FDA will evaluate and recommend COVID-19 vaccines going forward.

The Trump administration announced Tuesday that going forward, COVID-19 vaccines would be FDA-approved only for people over age 65 or those at risk for severe infection.